Raised risk of MI and mortality when starting sulfonylurea
Continuing metformin when introducing sulfonylureas in type 2 diabetes safer than switching Related items fromOnMedica Sugar not saturated fat is the major issue for CVD Experts query risks of pioglitazone Regulators suspend Avandia over safety concerns Daily aspirin use linked to major bleeding Use of DPP-4 inhibitors associated with increased risk of IBD
Source: OnMedica Latest News - Category: UK Health Source Type: news
More News: Actos | Aspirin | Avandia | Bleeding | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Saturated Fat | Sugar | UK Health